Publications

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

In The Journal of Clinical Pharmacology 2020, 00(0) 1–11 Authors Lionel Renaud, MSc , Kristell Lebozec, MSc, Christine Voors-Pette, MD, Peter Dogterom, PhD, Philippe Billiald, PharmD, Martine Jandrot Perrus, MD, Yannick Pletan, MD, and Matthias Machacek, PhD Abstract Glenzocimab (ACT017) is a humanized monoclonal antigen-binding fragment (Fab) directed against the human platelet glycoprotein VI, a key […]
Read more

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis In Neurology | Volume 93, Number 18 published on May, 29th 2019 Authors Lucas Di Meglio, MD, Jean-Philippe Desilles, MD, PhD, Véronique Ollivier, PhD, Mialitiana Solo Nomenjanahary, MSci, Sara Di Meglio, MSci, Catherine Deschildre, MSci, Stéphane Loyau, MSci, Jean-Marc Olivot, MD, PhD, Raphael Blanc, […]
Read more

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial In Arteriosclerosis, Thrombosis, and Vascular Biology; 2019; Vol 39 Issue 5; 956-964. Published on April 25th, 2019 Authors Christine Voors-Pette, Kristell Lebozec, Peter Dogterom, Laurie Jullien, Philippe Billiald, Pauline Ferlan, Lionel Renaud, Olivier Favre-Bulle, Gilles Avenard, Matthias […]
Read more

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development In New Biotechnology, 2018 Authors Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, Olivier Favre-Bulle, and Philippe Billiald. Abstract Monoclonal antibody fragments (Fab) are a promising class of therapeutic agents. Fabs are aglycosylated […]
Read more

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI In Haematologica 2018 Volume 103(5):898-907, published on Feb, 22nd 2018 Authors Pierre H Mangin, Marie-Blanche Onselaer,  Nicolas Receveur, Nicolas Le Lay,  Alexander T Hardy, Clare Wilson, Ximena Sanchez, Stéphane Loyau, Arnaud Dupuis, Amir K Babar, Jeanette LC Miller, Helen Philippou, Craig E Hughes, Andrew B Herr, Robert AS […]
Read more

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks In mAbs, 2017, VOL. 0, NO. 0, 1–14, published on Jun, 9th 2017 Authors Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, Olivier Favre-Bulle, and Philippe Billiald. Abstract Glycoprotein VI is a platelet-specific collagen receptor critical for in […]
Read more
Page 1 of 212